GB Sciences Louisiana can now commence full operations in the main medical cannabis production facility.
This facility is equipped with modular clean room technology for use in the production of plants and formulation of final products. The main production facility has more than five times the production capacity of the small exterior facility that GB Sciences Louisiana has been operating. This increase in space will allow for a perpetual harvest cycle, ensuring a continuous supply of product for patients with qualifying disease states.
Two previous successful harvests in the small exterior facility will allow GB Sciences Louisiana to soon begin the creation of final formulations. These formulations will be submitted to LDAF for final testing and ultimately distributed to the nine licensed pharmacies around the state.
“This is a great day for patients,” said John Davis, GB Sciences Louisiana president. “Full-scale operations mean a consistent and continuous supply of medical cannabis. We are thrilled to move into our main facilities.”
The LSU AgCenter conducted a thorough competitive public bid process in 2017 and examined and selected GB Sciences Louisiana as its public-private partner. GB Sciences was approved by LDAF in August 2018 to grow, extract and formulate in a small exterior facility while construction on the main production facility was underway. GB Sciences Louisiana completed the construction of the main production facility in October 2018. Since that date, the facility has received a certificate of occupancy from LDAF, and the standard operating procedures have been approved.
“The LSU AgCenter and GB Sciences Louisiana have worked diligently on this initiative since GB’s selection in September 2017. We are very happy to have this milestone completed, and we look forward to getting this much-needed product out to the patients of Louisiana,” said William B. Richardson, LSU vice president for agriculture.
The LSU AgCenter and the LSU College of Agriculture